首页> 外国专利> The mammal which excludes the kit null person who utilizes the screening manner of the material which utilizes the galectin 3 induction potency, the diagnostic manner and these

The mammal which excludes the kit null person who utilizes the screening manner of the material which utilizes the galectin 3 induction potency, the diagnostic manner and these

机译:不包括利用利用半乳凝素3诱导力的物质的筛选方式,诊断方式以及这些的试剂盒无效者的哺乳动物

摘要

PROBLEM TO BE SOLVED: To screen a substance which induces hepatpathy by measuring galeclin-3 inducibility.;SOLUTION: This substance screening method for giving a substance to be tested to a mammal except a human, lever tissue, or cultured hepatocytes and measuring gallectin-3 inducibility, a method for determining the condition of a liver by measuring gallectin-3 and the amount of a related substance thereof, and a kit utilizing these methods are provided. The detection of an increase of gallectin-3 in a liver is an index for determining the condition of drug-induced injuries of hepatocytes, the presence of inflammation of hepatocytes, their restoration, existence at restoration, and restorable hepatocytes thereafter. Its effect is generally applied not only to medication-induced and alcoholic hepatopathy but also to various types of infectious hepatitis. In general medication development, by measuring the gallectin-3 inducibility of compounds to be tested in hepatocytes, it is possible to easily screen and exclude highly hepatopathic compounds. In addition, the transcription of the gallectin-3 genes is accelerated by a natural transcription factor protein. Therefore, by chemically synthesizing a substance without toxicity which accelerates the synthesis of the gallectin-3 gene transcription factor protein in a liver, it is possible to use it as a therapeutic agent for carious types of hepatopathy including viral hepatitis.;COPYRIGHT: (C)2002,JPO
机译:解决的问题:通过测量galeclin-3诱导力来筛选可诱发肝病的物质;解决方案:此物质筛选方法可将除人类,杠杆组织或培养的肝细胞外的哺乳动物接受测试的物质给予检测,并测定没食子素参照图3,提供了通过测量galectin-3及其相关物质的量来确定肝脏状况的方法以及利用这些方法的试剂盒。肝脏中gallectin-3的增加的检测是确定药物诱导的肝细胞损伤情况,肝细胞炎症的存在,它们的恢复,恢复时的存在以及此后可恢复的肝细胞的指标。它的作用通常不仅适用于药物引起的酒精性肝病,而且还适用于各种类型的传染性肝炎。在一般的药物开发中,通过测量肝细胞中待测化合物的gallectin-3诱导性,可以轻松筛选和排除高度肝病性化合物。此外,galectin-3基因的转录由天然转录因子蛋白加速。因此,通过化学合成无毒物质来加速肝脏中Gallectin-3基因转录因子蛋白的合成,可以将其用作龋齿型肝病(包括病毒性肝炎)的治疗剂。日本特许厅

著录项

  • 公开/公告号JP4035562B2

    专利类型

  • 公开/公告日2008-01-23

    原文格式PDF

  • 申请/专利权人 国立大学法人富山大学;

    申请/专利号JP20020021636

  • 发明设计人 平賀 紘一;

    申请日2002-01-30

  • 分类号G01N33/68;G01N33/50;C12Q1/02;G01N33/15;

  • 国家 JP

  • 入库时间 2022-08-21 20:18:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号